WallStSmart

biote Corp (BTMD)vsFresenius Medical Care Corporation (FMS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Fresenius Medical Care Corporation generates 10485% more annual revenue ($19.43B vs $183.53M). FMS leads profitability with a 4.8% profit margin vs 3.2%. BTMD trades at a lower P/E of 8.8x. FMS earns a higher WallStSmart Score of 58/100 (C).

BTMD

Avoid

33

out of 100

Grade: F

Growth: 3.3Profit: 5.5Value: 8.3Quality: 7.0
Piotroski: 5/9Altman Z: 2.74

FMS

Buy

58

out of 100

Grade: C

Growth: 4.7Profit: 5.0Value: 9.3Quality: 6.0
Piotroski: 6/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BTMDUndervalued (+47.0%)

Margin of Safety

+47.0%

Fair Value

$4.00

Current Price

$1.22

$2.78 discount

UndervaluedFair: $4.00Overvalued
FMSUndervalued (+68.5%)

Margin of Safety

+68.5%

Fair Value

$76.29

Current Price

$22.69

$53.60 discount

UndervaluedFair: $76.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BTMD2 strengths · Avg: 10.0/10
P/E RatioValuation
8.8x10/10

Attractively priced relative to earnings

Debt/EquityHealth
-1.9610/10

Conservative balance sheet, low leverage

FMS3 strengths · Avg: 9.3/10
P/E RatioValuation
12.0x10/10

Attractively priced relative to earnings

Price/BookValuation
0.8x10/10

Reasonable price relative to book value

PEG RatioValuation
0.748/10

Growing faster than its price suggests

Areas to Watch

BTMD4 concerns · Avg: 2.8/10
Market CapQuality
$41.70M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
3.2%3/10

3.2% margin — thin

Revenue GrowthGrowth
-9.5%2/10

Revenue declined 9.5%

FMS4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
1.4%4/10

1.4% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Return on EquityProfitability
7.5%3/10

ROE of 7.5% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : BTMD

The strongest argument for BTMD centers on P/E Ratio, Debt/Equity.

Bull Case : FMS

The strongest argument for FMS centers on P/E Ratio, Price/Book, PEG Ratio. PEG of 0.74 suggests the stock is reasonably priced for its growth.

Bear Case : BTMD

The primary concerns for BTMD are Market Cap, Return on Equity, Profit Margin. Thin 3.2% margins leave little buffer for downturns.

Bear Case : FMS

The primary concerns for FMS are Revenue Growth, Altman Z-Score, Return on Equity. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

BTMD carries more volatility with a beta of 1.61 — expect wider price swings.

FMS is growing revenue faster at 1.4% — sustainability is the question.

FMS generates stronger free cash flow (620M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

FMS scores higher overall (58/100 vs 33/100). BTMD offers better value entry with a 47.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

biote Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

biote corp. The company is headquartered in Irvine, Texas.

Fresenius Medical Care Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.

Visit Website →

Want to dig deeper into these stocks?